Weill Neurohub joins with Genentech, Roche to advance neuroscience research
The University of California, San Francisco (UCSF) and UC Berkeley today announced a long-term research partnership with Genentech, a member of the Roche Group, and its parent company, Roche Holding AG, to speed the development of new therapeutics for debilitating brain diseases and disorders of the central nervous system (CNS), such as Alzheimer’s, Parkinson’s, Huntington’s, ALS and autism. UCSF and UC Berkeley will receive up to $53 million from Genentech over the course of the 10-year collaboration.
The partnership, dubbed the Alliance for Therapies in Neuroscience (ATN), is a major milestone for the Weill Neurohub, a joint research collaboration between UCSF, UC Berkeley and the University of Washington. The Weill Neurohub was launched in 2019 with gifts from the Weill Family Foundation to focus researchers from many different disciplines on one of society’s most pressing health problems — disorders of the brain and nervous system, which afflict over 1 billion people and represent the leading cause of disability worldwide. Just one year later, the Genentech and Roche partnership provides a powerful mechanism for putting those collaborations into action with a focus on developing long-needed therapies for these disorders.
